文献速递眼底病与葡萄膜炎小儿眼科与斜弱视

微滴散瞳剂用于早产儿视网膜病变筛查的有效性与安全性:MyMiROPS随机临床试验

Efficacy and Safety of Mydriatic Microdrops for Retinopathy of Prematurity Screening: The MyMiROPS Randomized Clinical Trial.
PubMed 文献 · JAMA Ophthalmol · 2025-01-01

这项双盲、非劣效性、交叉设计的随机临床试验在希腊北部一家三级中心纳入83名接受早产儿视网膜病变筛查的早产儿,比较1.67%去氧肾上腺素与0.33%托吡卡胺混合液微滴与标准滴的散瞳效果。微滴在45分钟时散瞳效果优于标准滴,在90和120分钟时非劣效;标准滴后观察到较低的血氧饱和度和较高的24小时高血压发作百分比。

要点

  • 微滴在45分钟散瞳效果优于标准滴(均差0.12;Bonferroni校正95%CI 0.01至0.23;P=.008)。
  • 微滴在90分钟(Bonferroni校正95%CI -0.10至0.17)和120分钟(Bonferroni校正95%CI -0.18至0.14)非劣效于标准滴。
  • 标准滴后45分钟和90分钟血氧饱和度较低,24小时高血压发作百分比较高。

核心结论

  • 微滴与标准滴的稀释散瞳混合液相比具有非劣效性,微滴后全身不良事件减少,并确定了早产儿中去氧肾上腺素滴眼液的药代动力学特征。

研究设计与样本

  • 双盲、非劣效性、交叉设计的随机临床试验,纳入83名在希腊北部一家三级中心接受早产儿视网膜病变筛查的婴儿,筛查时间为2021年9月至2023年1月。
  • 纳入标准为胎龄低于32周和/或出生体重低于1501克的婴儿,或由主治新生儿科医生因合并症转诊的超出这些阈值的婴儿。
  • 干预为按随机分配序列给予微滴或标准滴的稀释混合液,洗脱期为1周。

主要发现

  • 微滴在45分钟时散瞳效果优于标准滴(均差0.12;Bonferroni校正95%CI 0.01至0.23;P=.008)。
  • 微滴在90分钟(Bonferroni校正95%CI -0.10至0.17)和120分钟(Bonferroni校正95%CI -0.18至0.14)非劣效于标准滴。
  • 标准滴后45分钟血氧饱和度较低(均差0.66;95%CI 0.09至1.24;P=.03),90分钟血氧饱和度较低(均差0.58;95%CI 0.03至1.14;P=.04)。
  • 标准滴后24小时高血压发作百分比较高(微滴中位数[IQR] 0.10%[0.02%-0.19%] vs 标准滴0.14%[0.06%-0.40%];P=.01)。
  • 一室模型伴一级吸收最能描述药代动力学数据。

关键数值与推荐

  • 预设非劣效性界值为-0.4毫米。
  • 瞳孔水平直径在45、90和120分钟使用定制尺以0.5毫米增量测量。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Commercial mydriatics administered in preterm infants during retinopathy of prematurity (ROP) screening have been associated with various cardiorespiratory and gastrointestinal adverse events. OBJECTIVE: To examine whether microdrops of a combined mixture of 1.67% phenylephrine and 0.33% tropicamide are noninferior to standard drops regarding mydriatic efficacy at 45, 90, and 120 minutes. The occurrence of systemic adverse events and systemic absorption of phenylephrine eyedrops were additional secondary outcomes. DESIGN, SETTING, AND PARTICIPANTS: This randomized clinical trial with a double-masked, noninferiority, crossover design included infants undergoing ROP screening at a tertiary center in Northern Greece from September 2021 to January 2023. Eligible participants were infants with gestational age below 32 weeks and/or birthweight under 1501 g, or infants beyond these thresholds referred by an attending neonatologist due to comorbidities. INTERVENTIONS: Either microdrops or standard drops of the diluted mixture were administered at a random allocation sequence with a 1-week washout period. MAIN OUTCOMES AND MEASURES: The horizontal pupil diameter at 45, 90, and 120 minutes was measured using a customized ruler in 0.5-mm increments. Mixed-effects linear regression models were developed, and the confidence interval (CI) approach was used for assessing noninferiority. The predefined noninferiority margin was -0.4 mm. Heart rate; oxygen saturation; blood pressure measurements at 45, 90, and 120 minutes; 24-hour hypertensive episodes; and 48-hour systemic adverse events were assessed. Phenylephrine concentration in peripheral blood within 3 hours postinstillation was measured using hydrophilic liquid chromatography-tandem mass spectrometry. Pooled pharmacokinetic parameters were calculated based on a developed mathematical model. RESULTS: A total of 83 infants were randomized (mean [SD] gestational age, 29.7 [2.0] weeks; mean [SD] birth weight, 1277 [374] g). Microdrops proved to be superior regarding mydriatic efficacy at 45 minutes (mean difference, 0.12; Bonferroni-corrected 95% CI, 0.01 to 0.23; P = .008) and noninferior at 90 minutes (Bonferroni-corrected 95% CI, -0.10 to 0.17) and 120 minutes (Bonferroni-corrected 95% CI, -0.18 to 0.14). Lower levels of oxygen saturation at 45 minutes (mean difference, 0.66; 95% CI, 0.09 to 1.24; P = .03) and 90 minutes (mean difference, 0.58; 95% CI, 0.03 to 1.14; P = .04) and higher percentage of 24-hour hypertensive episodes (median [IQR] percentage of hypertensive episodes: microdrops, 0.10% [0.02%-0.19%] vs standard drops, 0.14% [0.06%-0.40%]; P = .01) were observed after standard drops. A 1-compartment model with first-order absorption best described the pharmacokinetic data. CONCLUSION AND RELEVANCE: To our knowledge, this is the first study establishing noninferiority of microdrops compared with standard drops of a diluted mydriatic mixture, showing reduced systemic adverse events after microdrops and determining the pharmacokinetic profile of phenylephrine eyedrops in preterm infants. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT05043077.

来源:JAMA Ophthalmol,查看原文。版权归原作者所有。

引用

  1. Seliniotaki AK, Lithoxopoulou M, Virgiliou C, et al. Efficacy and Safety of Mydriatic Microdrops for Retinopathy of Prematurity Screening: The MyMiROPS Randomized Clinical Trial. JAMA Ophthalmol. 2025. PMID: 39724200. doi:10.1001/jamaophthalmol.2024.5462

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。